Utility-QALYs | Mapi Research Trust

Lead text placeholder. Lorem ipsum dolor sit amet, consectetur adipisicing elit.

Articles

2019. Hoxer CS et al. – Utility valuation of health states for haemophilia and related complications in Europe and in the United States
2018. Davies EW et al. – Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension
2018. Jendle J et al. – A utility valuation study assessing the impact of postprandial glucose control on quality of life of individuals with type 1 or type 2 diabetes
2018. Kay G et al. – Cost-effectiveness of TYRX absorbable antibacterial envelope for prevention of cardiovascular implantable electronic device infection
2018. Guirant L et al. – Health-related quality of life during the first year after a hip fracture: Results of the Mexican arm of the International Cost and Utility Related to Osteoporotic Fractures Study (MexICUROS)
2018. Pialoux G et al. – Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France
2017. Prabhu VS et al. – Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States
2017. Prabhu V et al. – Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK
2017. Mennini FS et al. – Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
2017. Soini E et al. – Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland
2017. Kauf TL et al. – Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections
2017. Young et al. – Cost-utility evaluation of vortioxetine in patients with major depressive disorder experiencing inadequate response to alternative antidepressants in the United Kingdom
2017. Cawston et al. – NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK
2017. Largeron N et al. – An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany
2017. Stahmeyer JT et al. – Cost-effectiveness of treating hepatitis C with lofosbuvir/ledipasvir in Germany
2017. Igarashi A et al. – Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan
2017. Igarashi A et al. – Cost-utility analysis of ledipasvir/ sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan
2016. Bianic F et al. – Cost-effectiveness of everolimus plus reduced tacrolimus in de novo liver-recipients in the Italian setting
2016. Jürisson M et al. – Quality of life, resource use, and costs related to hip fracture in Estonia
2016. Lopez-Belmonte JL et al. – The use of Zostavax in Spain: The economic case for vaccination of individuals aged 50 years and older
2016. Chevalier J et al. – Cost-effectiveness of treatments for relapsing remitting multiple sclerosis: A French societal perspective
2015. Pialoux G et al. – Cost-effectiveness of dolutegravir in HIV-1 treatment-experienced (TE) patients in France
2015. Tallman M et al. – Cost-effectiveness analysis of treating acute promyelocytic leukemia patients with arsenic trioxide and retinoic acid in the United States.
2015. Cure S et al. – Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients
2015. Cure S et al. – Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy
2014. Huisman EL et al. – Economic evaluation of pooled solvent/detergent treated plasma versus single donor fresh-frozen plasma in patients receiving plasma transfusions in the United States
2014. Huisman EL et al. – Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (octaplasLG®) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada
2014. Karabis A et al. – Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: An analysis over 5 years
2013. Chouaid C et al. – Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: A prospective cross-sectional patient survey in a real world setting
2013. Borgström F et al. – The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)–quality of life during the first 4 months after fracture
2013. Svedbom A et al. – Balloon kyphoplasty compared to vertebroplasty and nonsurgical management in patients hospitalised with acute osteoporotic vertebral compression fracture: A UK cost-effectiveness analysis
2012. Reichardt P et al. – Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) study
2011. Jansen JP et al. – Cost-effectiveness evaluation of etoricoxib versus celecoxib and nonselective NSAIDs in the treatment of ankylosing spondylitis in Norway
2011. Vissers DC et al. – An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer
2010. Van Eerd MC et al. – Cost-effectiveness study comparing pharmaceutically licensed plasma for transfusion (OctaplasLG®) versus fresh frozen plasma (FFP) in critically Ill patients in the UK
2010. Jansen JP et al. – Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis
2010. Verdian L et al. – Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom
2009. Parthan et al. – Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck
2009. Jansen JP et al. – Cost-effectiveness evaluation of ertapenem versus piperacillin/ tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance
2009. Jansen JP et al. – Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK
2008. Jansen JP et al – Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands

Posters & Presentations

2017. ISPOR European Congress – Minimal Impact on Patients’ Health Utilities Associated with Adverse Events in Metastatic Merkel Cell Carcinoma Patients on Treatment with Avelumab
2017. ISPOR European Congress – Estimating utilities/disutilities for high risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events
2017. ISPOR European Congress – Development and utility valuation of health states for haemophilia and related complications in Europe and in the USA
2017. ISPOR Annual International Meeting – Non-progression on treatment with avelumab contributed to gains in health utility scores with metastatic Merkel Cell Carcinoma
2016. ISPOR European Congress – Health State Utilities for Persistent, Recurrent or Metastatic Cervical Cancer in France
2016. ISPOR European Congress – Estimating the Utility Associated with Mode of Treatment Administration in Gaucher Disease
2016. ISPOR European Congress – Understanding the Utility Value of Patients with Heavily Pre-Treated Multiple Myeloma
2016. ISPOR European Congress – Understanding the Utility Value of Patients with Heavily Pre-Treated Multiple Myeloma
2016. ASCO Annual Meeting – Association of Disease Progression, Health-Related Quality of Life, and Utility in Patients with Advanced, Nonfunctional, Well-Differentiated Gastrointestinal or Lung Neuroendocrine Tumors in the Phase 3 Radiant-4 Trial
2015. ISPOR European Congress – Utilities in HTA: Challenges for Theory and Practice Now and in the Future
2015. ISPOR Annual International Meeting – Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure Registry
2015. ISPOR Annual International Meeting – Cost-Utility of Vortioxetine Versus Venlafaxine XR in the Treatment of Major Depressive Disorder in South Korea
2012. ISPOR European Congress – Converting EORTC QOL-C30 Scores to Utility Values: Is it Plausible?
2010. ISPOR European Congress – Utility Elicitation Study in the UK General Public for Late Stage Chronic Lymphocytic Leukaemia
2009. ISPOR Annual International Meeting – Cost- Effectiveness of Valsartan in Japan: Results from the JIKEI Heart Study
2008. ISPOR European Congress – Eliciting Utility Scores for Health States Associated with Lennox-Gastaut Syndrome
2008. ISPOR European Congress – Rufinamide in the Adjunctive Treatment of Lennox-Gastaut Syndrome (LGS): A Cost Effectiveness Analysis.
2008. ISPOR European Congress – Raising the Value of Direct Utility Measurement Approaches for Pharmaceutical Market Access Decision-Making: Is it Possible?
2008. ISPOR European Congress – Patient-Reported Outcome (PRO) and Utility Data in Market Access Decision-Making
2008. ISPOR European Congress – Health State Preference Study Mapping the Change over the Course of the Disease Process in Chronic Lymphocytic Leukaemia (CLL)